Close Menu


NEW YORK (GenomeWeb) – While industry observers might disagree about whether GeneDx's decision to apply for inter partes review (IPR) of 11 patents held by Myriad Genetics will work in its favor, they generally concur that it is a quicker and less costly strategy than litigation.

This article has been updated to include a statement from Myriad Genetics.

Title: RNA Interference Modulators of Hedgehog Signaling and Uses Thereof
Patent Number: 8,802,639
Filed: March 24, 2005

Title: Sustained-release Nucleic Acid Matrix Compositions
Patent Number: 8,795,726
Filed: Jan. 18, 2011

Title: RNA Sequence-specific Mediators of RNA Interference
Patent Number: 8,790,922
Filed: Oct. 4, 2010

Title: Oligoribonucleotides and Methods of Use Thereof for Treatment of Alopecia, Acute Renal Failure, and Other Diseases
Patent Number: 8,765,699

Title: Methods for Normalizing and for Identifying Small Nucleic Acids
Patent Number: 8,741,569
Filed: Oct. 23, 2009

Title: Compositions and Methods for Treatment of Prostate and Other Cancer
Patent Number: 8,722,872
Filed: June 23, 2009

Title: Methods for Eliminating or Reducing the Expression of a Gene in a Filamentous Fungal Strain
Patent Number: 8,716,023

Title: System for Targeted Delivery of Therapeutic Agents
Patent Number: 8,709,483
Filed: Sept. 26, 2008


A new analysis founds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.